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Novel Sunitinib Strategy in Metastatic Renal Cell
Carcinoma on Hemodialysis: Intermittent Dose of
Sunitinib after Hemodialysis
I n t r o d u c t i o n
Long term dialysis is a risk factor for renal cell carcinoma (RCC)
since the prevalence of RCC in hemodialysis or renal transplant patients
is 40 to 100 times higher than that of the general population. The kidney
and urinary tract organs are susceptible to systemic carcinogenic effects
extending from biochemical and immunologic changes that occur with
renal pathologies, resulting in loss of proper renal function (1-3).
In spite of increasing numbers of RCC patients with renal impair-
ment, most clinical trials do not include these patients and there is
therefore little knowledge regarding systemic chemotherapy in end
stage renal disease (ESRD) patients (4). Sunitinib is an oral tyrosine
kinase inhibitor (TKI) targeting the vascular endothelial growth factor
receptor and the platelet derived growth factor receptor. Given as
first-line treatment in metastatic RCC, it has shown clinical activity
in a phase III randomized trial and is the current standard treatment
for metastatic RCC (5-8). It is usually administered as a once daily
dose of 50 mg in a schedule of 4 weeks on and 2 weeks off. Sunitinib
and its main metabolite, SU12662, are mainly eliminated in the feces
and only 15 to 20% of the dose is cleared by kidney (9). The proper
dose and schedule of sunitinib have yet to be established in patients
with metastatic RCC on hemodialysis. In addition, long-term treatment
outcome and tolerability of sunitinib in patients on hemodialysis have
not been reported.
Here, we describe two patients with metastatic RCC on hemodialysis
who were treated with intermittent doses of sunitinib in accordance
with the patient’s renal function.
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The proper dose and schedule of sunitinib have yet to be established for patients with
metastatic renal cell carcinoma (RCC) on hemodialysis. We reviewed two patients with
metastatic RCC on hemodialysis who had been treated with sunitinib in Yonsei Cancer
Center, Yonsei University College of Medicine. Fifty milligrams of sunitinib was administered
intermittently after each hemodialysis session (3 or 4 times a week). Overall responses were
partial response in both cases. Progression-free survivals were 16 and 6 months,
respectively, at the time of reporting (April 2010). Both subjects tolerated the treatment.
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1 Patient 
A 53-year old male underwent right nephrectomy for stage II
(pT2N0M0) clear cell RCC in 1996. In 2004, a mass was detected
in the right gluteus muscle which proved to be metastatic RCC on
biopsy. He underwent radiation therapy after which he was confirmed
as having no residual lesions. Thereafter he developed impaired
renal function with serum blood urea nitrogen (BUN) 85 mg/dL and
creatinine 7.5 mg/dL. Hemodialysis was begun three times a week
in 2004. In 2005, right lung wedge resection was performed due to a
metastatic lesion (Fig. 1A) and he was free of recurrent or metastatic
lesions until January 2009 when multiple lung metastases
developed. The prognostic risk category of the patient was
intermediate as defined by the Memorial Sloan-Kettering Cancer
Center (MSKCC) risk model, with Karnofsky performance status
90%, serum hemoglobin 10.7 mg/dL, serum corrected calcium 10.6
mg/dL, lactate dehydrogenase (LDH) 168 IU/L. Baseline computed
tomography (CT) scan of the chest showed right hilar lymph node
enlargement, a chest wall mass and multiple lung metastases. Fifty
milligrams of sunitinib was administered intermittently after each
hemodialysis session (3 times a week) from 15 January 2009. The
best response was partial response (PR) with 30% size reduction from
baseline (Fig. 2). At the time of reporting, April 2010, the patient
was tolerating sunitinib relatively well and the progression-free
survival (PFS) was 16 months. Most adverse effects observed were
neuropathy, facial edema, skin rash, yellowish skin pigmentation,
diarrhea, thrombocytopenia, anemia and leucopenia. All of these
toxicities were manageable (grade 1). Blood pressure was well
controlled with standard anti-hypertensive medications and there was
no evidence of hypothyroidism. Although, the patient has been
tolerating sunitinib, complications such as increasing chronic fatigue
and general weakness, resulting in decreased general performance and
activity, were apparent after 1 year of treatment.
2 Patient 
A 67-year old female was diagnosed with ESRD due to hypertension
and started hemodialysis in May 2006. After 1 month of hemodialysis,
a left kidney tumor developed and she underwent nephrectomy for
stage I (pT1N0M0) clear cell RCC. In May 2009, multiple metastatic
lesions began to develop in her right auricular, right forearm, right
axillary, and right scapular areas. She also developed additional lymph
nodes at her right hilum and multiple metastatic lesions in her lungs
and bones. Biopsies of her right auricular and forearm masses showed
metastatic clear cell RCC (Fig. 1B). The prognostic risk category of
the patient was intermediate as defined by the MSKCC risk model with
Karnofsky performance status 90%, serum hemoglobin 11.4 mg/dL,
serum corrected calcium 10.7 mg/dL, LDH 229 IU/L. Fifty
milligrams of sunitinib was administered intermittently after each
hemodialysis session (4 times a week) from November 2009. The
best response was PR with 34% size reduction from baseline after 4
months of treatment (Fig. 3). Adverse events such as aggravation of
hypertension or hypothyroidism did not occur. At the time of
reporting, April 2010, she was tolerating intermittent sunitinib well
and the PFS was 6 months.
D i s c u s s i o n
We compared our cases with 3 previously reported cases (in 2
reports) in which metastatic RCC patients on hemodialysis were
treated with sunitinib (Table 1) (10,11). All cases, including ours,
involved clear cell type RCC. The prognostic risk categories of the
patients in our report were intermediate as defined by the MSKCC
risk model, but there were no such descriptions in the previous reports.
There were similarities in the responses and toxicities of the previous
reports and ours. However, the dosage methods were different in
each report. Sunitinib was administered daily in 6-week cycles:
administration for 4 weeks followed by 2 weeks off treatment in
both previous reports. The sunitinib dose was 50 mg daily irrespective
of hemodialysis in Park’s report (11). In contrast, Zastrow et al. (10)
started with a sunitinib dose of 25 mg daily, irrespective of hemo-
dialysis, and increased to 37.5 mg and 50 mg according to the patients'
tolerance. Overall responses were complete response (CR) by the
patient in Park’s report (11), and CR by one patient and stable disease
by the other patient in Zastrow et al.’s report (10). However, the
dose intensity in these two reports was similar to that used with non-
ESRD patients, and it seemed that higher cumulative doses of the
sunitinib resulted in better responses. Our sunitnib dose intensity, 50
mg after each hemodialysis session (3 or 4 times a week), was much
lower than the dose intensities of the previous reports. Both patients
had achieved PR at the time of reporting and we expect to see im-
provements of their outcomes as the cumulative dose increases.
During the planning stages of our sunitinib therapy, we were unable
to find any guidelines for treatment of hemodialysis patients. We
therefore decided to treat patients with the dosage method described
above on the basis of three rationale: 1) the half-life of sunitinib is
40 to 60 hours; 2) reduced doses of usual cytotoxic drugs are used in
hemodialysis patients (4); 3) long-term tolerability sustains durable
response, especially with TKI treatments in RCC. Both subjects
tolerated the treatment without interruptions of sunitinib. Significantly,
the time to response (1 year) was longer than that seen with other
cytotoxic drugs or conventional sunitinib. Thus, it is important to
keep patients tolerating treatment in order to maintain prolonged
response. Furthermore, Hong et al. (12) reported that sunitinib
toxicities accumulated and were apparent after approximately 1 year
of sunitinib treatment in more than 50% of patients. Therefore, standard
dose long-term sunitinib treatment might aggravate underlying
hypertension and general weakness of ESRD patients. It is thus
important to find an effective dosage associated with minimal
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Fig. 2. Response evaluation of the CT scans in case 1. Target lesions were right hilar lymph node with 41.7 mm (A) and chest wall mass with
40.9 mm (G). Non-target lesions were multiple lung masses (D). After 2 months of treatment, multiple lung lesions started to decrease (B, E, H).
After 13 months of treatment, hilar lymph node decreased to 30.7 mm (C) and chest wall mass became 26.7 mm (I) with 30% of size reduction.
Non-target lesions also decreased without any new lesions (F).
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Fig. 1. The pathologic features of recurred lesions. Metastatic lesion of lung in case 1 (H&E, ×200) (A). Metastatic lesion of forearm, skin in
case 2 (H&E, ×400) (B).
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Fig. 3. Response evaluation of the CT scans and bone scans in case 2. Target lesion was right hilar lymph node with 34.4 mm (A). Non-target
lesions were multiple lesions of lung (C) and bone (E). After 4 months of treatment, the target lesion decreased to 22.6 mm (B), which was 34%
reduction, and non-target lesions also decreased (D, F).
Cancer Res Treat. 2010;42(3):180-184
184 CANCER  RESEARCH AND  TREATMENT
toxicity. In this regard, our dosage method would have the same
efficacy in metastatic RCC patients on hemodialysis as previous
reports and we suggest that it be widely adopted.
From our experiences with two patients, we suggest that the inter-
mittent treatment mode used here could be an alternative option for
treating metastatic RCC in the context of hemodialysis: fifty milli-
grams of sunitinib after each hemodialysis session.
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R e f e r e n c e s
Author/year Sex/age Histology
MSKCC* Dosage Response
PFS�
Toxicity
risk model (mo)
Chi Young Park/ M/54 Clear cell No data 50 mg daily CR� 20 G1 fatigue, nausea 
200911 G2 neutropenia,
thrombocytopenia
Stefan Zastrow et al./ M/41 Clear cell No data 25 mg � 37.5 mg CR 16 G3 amylase, lipase elevation
200910 M/44 Clear cell No data 25 mg � 37.5 mg SD§ 18 G1 & G2 hyperglycemia, 
� 50 mg anemia, thrombocytopenia
Yonsei Cancer Center/ M/53 Clear cell Intermediate 50 mg after HD‖ PR¶ 16 G1 neuropathy, skin rash, diarrhea
2010 on-dialysis day G1 anemia, leucopenia, 
thrombocytopenia
F/57 Clear cell Intermediate 50 mg after HD SD 6 None
on-dialysis day
Table 1. Reports of sunitinib treatment in metastatic renal cell carcinoma (RCC) patients on hemodialysis
*Memorial Sloan-Kettering Cancer Center, �progression-free survival, �complete response,  §stable disease, ‖hemodialysis, ¶partial response.
